EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The parasympathetic tone reduction and sympathetic tone enhancement, which are components of the autonomic nervous system (ANS) activity, increase the likelihood of malignant arrhythmias leading to ventricular fibrillation. Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) surgeries. Heart rate variability (HRV) is a physiological indicator of the effects of ANS activity on heart rate and is associated with a prognostic value for cardiac mortality. Dexmedetomidine has been shown to improve myocardial perfusion, reduce arrhythmia incidence, reduce inflammatory response, and reduce mortality in patients with coronary artery disease. The aim of this study investigate the effects of dexmedetomidine electrophysiologically on cardiac autonomic system by using HRV analysis for the purpose of sedation in patients who were followed up in the intensive care unit after coronary artery bypass graft surgery

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
• Treatments: Dexmedetomidine; Midazolam

Criteria

Inclusion Criteria:

• Patients with pre-operative normal sinus rhythm

• Ejection fraction (EF)> 45% on echocardiography (echocardiography) examination

• 25 and 65 years of age will be included.

Exclusion Criteria:

• Atrial fibrillation , atrial flutter, supraventricular tachycardia , AV block, ventricular extrasystole

• Cardiopulmonary bypass have been reported in patients with diabetes mellitus (DM),

• Chronic obstructive pulmonary disease (COPD),

• Previous cerebrovascular event will be excluded from the study.

• Patients receiving high-dose inotropic drug support after surgery (inotropic score of> 10 in the first 24 hours) and

• Patients re-operated for bleeding revision will be removed from the study.